Anti-obesity drugs and neural circuits of feeding

被引:80
|
作者
Adan, Roger A. H. [1 ]
Vanderschuren, Louk J. M. J. [1 ]
la Fleur, Susanne E. [1 ]
机构
[1] UMC Utrecht, Rudolf Magnus Inst Neurosci, Dept Neurosci & Pharmacol, NL-3584 CG Utrecht, Netherlands
关键词
D O I
10.1016/j.tips.2008.01.008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Most of the drugs that have entered the market for treating obesity were originally developed to treat psychiatric diseases. During the past decade, understanding of the neural circuits that underlie food intake has increased considerably. Different aspects of ingestive behavior such as meal termination, meal initiation and overconsumption of highly rewarding and palatable foods are modulated by different neuroanatomical structures. Integration of the action of many signaling molecules (e.g. hormones, neurotransmitters and neuropeptides) in these structures results in a response that, ultimately, modulates food intake. Thus, the type of drug required by an obese patient might depend on the individual cause of obesity. In this article, we summarize the neural circuits that regulate food intake and we provide a framework for understanding how obesity drugs function. Several potential drug targets are expressed in different neural circuits, implying that current and future obesity drugs act on partially overlapping systems that control food intake.
引用
收藏
页码:208 / 217
页数:10
相关论文
共 50 条
  • [41] A Risk-Benefit Assessment of Anti-Obesity Drugs
    Jaroslaw Kolanowski
    Drug Safety, 1999, 20 : 119 - 131
  • [42] Characteristics of diabetic patients starting anti-obesity drugs
    Willemen, M. J. C.
    Mantel-Teeuwisse, A. K.
    Straus, M. J. M.
    Leufkens, H. G. M.
    Egberts, A. C. G.
    DRUG SAFETY, 2007, 30 (10) : 968 - 968
  • [43] Anti-obesity drugs recalled from global market
    Ault, A
    LANCET, 1997, 350 (9081): : 867 - 867
  • [44] Anti-obesity drugs: a review about their effects and their safety
    Derosa, Giuseppe
    Maffioli, Pamela
    EXPERT OPINION ON DRUG SAFETY, 2012, 11 (03) : 459 - 471
  • [45] Use of anti-obesity drugs among college students
    de Carvalho e Martins, Maria do Carmo
    de Souza Filho, Manoel Dias
    Moura, Felipe Scipiao
    Ribeiro de Carvalho, Juliana de Sousa
    Mueller, Marina Costa
    Neves, Rebeka Valenca
    Mousinho, Patricia Coelho
    Lima, Iuri Paz
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2011, 57 (05): : 570 - 576
  • [46] Anti-obesity drugs: Use, mechanisms and clinical importance
    Adam, O
    Forth, W
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2001, 39 (06) : 232 - 238
  • [47] Mechanisms underlying current and future anti-obesity drugs
    Adan, Roger A. H.
    TRENDS IN NEUROSCIENCES, 2013, 36 (02) : 133 - 140
  • [48] Challenges in the assessment of reproductive toxicology of anti-obesity drugs
    Bolze, F.
    Rojas, J. M.
    Bhuwania, R.
    Egecioglu, N. E.
    Dalgaard, M.
    Andersen, L. W.
    TOXICOLOGY LETTERS, 2018, 295 : S30 - S30
  • [49] Anti-Obesity Drugs: A Review about Their Effects and Safety
    Kang, Jun Goo
    Park, Cheol-Young
    DIABETES & METABOLISM JOURNAL, 2012, 36 (01) : 13 - 25
  • [50] First do no harm with anti-obesity and other drugs
    Toussaint, Bruno
    BMJ-BRITISH MEDICAL JOURNAL, 2013, 346